INTERVENTION 1:	Intervention	0
Pegylated Liposomal Doxorubicin (PLD) Based Regimen	Intervention	1
doxorubicin	CHEBI:28748,BAO:0000639	20-31
PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)	Intervention	2
cyclophosphamide	CHEBI:4026	35-51
paclitaxel	CHEBI:45863	241-251
INTERVENTION 2:	Intervention	3
Doxorubicin Based Regimen	Intervention	4
doxorubicin	CHEBI:28748,BAO:0000639	0-11
doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)	Intervention	5
doxorubicin	CHEBI:28748,BAO:0000639	0-11
cyclophosphamide	CHEBI:4026	46-62
paclitaxel	CHEBI:45863	153-163
Inclusion Criteria:	Eligibility	0
Subjects with operable, node-positive or high-risk node-negative (see #3 below) HER2-positive breast carcinoma are eligible for the study, provided they satisfy the following criteria.	Eligibility	1
breast carcinoma	HP:0003002,DOID:3459	94-110
Subjects must demonstrate willingness to and be able to participate in the study and to adhere to dose and visit schedules	Eligibility	2
Subjects must be of female gender and >= 18 years of age	Eligibility	3
female	PATO:0000383	20-26
age	PATO:0000011	53-56
Subjects must have been diagnosed with operable, histologically confirmed adenocarcinoma of the breast with no clinical or radiological evidence of metastatic disease but with otherwise high or intermediate risk tumor characteristics:	Eligibility	4
adenocarcinoma	DOID:299	74-88
breast	UBERON:0000310	96-102
disease	DOID:4,OGMS:0000031	159-166
node-positive: T1-3, N1-2, M0 (level of T [tumor involvement], N [lymph node involvement], & M [matastases]) OR	Eligibility	5
t	CHEBI:36371,BAO:0001260	9-10
t	CHEBI:36371,BAO:0001260	15-16
t	CHEBI:36371,BAO:0001260	40-41
t	CHEBI:36371,BAO:0001260	43-44
t	CHEBI:36371,BAO:0001260	59-60
t	CHEBI:36371,BAO:0001260	87-88
t	CHEBI:36371,BAO:0001260	98-99
t	CHEBI:36371,BAO:0001260	101-102
lymph	UBERON:0002391	66-71
node-negative AND at least one of the following features:	Eligibility	6
Tumor >2 cm or	Eligibility	7
Tumor >1 cm and	Eligibility	8
Negative estrogen receptor/progesterone receptor (ER/PR) or	Eligibility	9
estrogen	CHEBI:50114,BAO:0000760	9-17
receptor	BAO:0000281	18-26
receptor	BAO:0000281	40-48
Malignancy Grade 2-3 or	Eligibility	10
Presence of peritumoral vascular invasion or	Eligibility	11
Age <35 years	Eligibility	12
age	PATO:0000011	0-3
HER2-positive by fluorescence in situ hybridization (FISH)(with gene amplification) or 3+ using	Eligibility	13
gene	BAO:0000582	64-68
immunohistochemistry	Eligibility	14
immunohistochemistry	BAO:0000415	0-20
Subjects must have had complete resection (R0) of the primary tumor and axillary lymph nodes (or must have negative sentinel node[s])	Eligibility	15
lymph	UBERON:0002391	81-86
Baseline left ventricular ejection fraction (LVEF) by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) >=55%	Eligibility	16
left	HP:0012835	9-13
ejection fraction	CMO:0000180	26-43
Easter Cooperative Oncology Group (ECOG)-performance status of 0-1	Eligibility	17
group	CHEBI:24433	28-33
Adequate postoperative bone marrow function with neutrophils >=1.5 x 10^9/l, platelets >=100 x 10^9/l and hemoglobin >= lower limit of normal (LLN)	Eligibility	18
bone marrow	UBERON:0002371	23-34
function	BAO:0003117,BFO:0000034	35-43
x	LABO:0000148	67-68
x	LABO:0000148	93-94
hemoglobin	CHEBI:35143	106-116
Adequate renal function: calculated creatinine clearance >=50 ml/min	Eligibility	19
function	BAO:0003117,BFO:0000034	15-23
creatinine clearance	CMO:0000765	36-56
Adequate postoperative liver function with a total bilirubin < upper limit of normal (ULN), alkaline phosphatase <2.5 times the ULN and aspartate aminotransferase (AST) <1.5 times the ULN	Eligibility	20
liver	UBERON:0002107	23-28
function	BAO:0003117,BFO:0000034	29-37
phosphatase	GO:0016791,BAO:0000295	101-112
aspartate	CHEBI:29995	136-145
Subjects must be free of any clinically relevant disease that would, in the principal investigator's and/or sponsor's opinion, interfere with the conduct of the study or study evaluations	Eligibility	21
disease	DOID:4,OGMS:0000031	49-56
Subjects of childbearing potential (including women who are less than one year postmenopausal and will be sexually active during the study) must agree to use a medically accepted method of contraception, while receiving protocol-specified medication and for 30 days (or as per local requirements) after stopping the medication or be surgically sterilized prior to screening	Eligibility	22
year	UO:0000036	74-78
active	PATO:0002354	115-121
Subjects must be able to provide written informed consent	Eligibility	23
Exclusion Criteria:	Eligibility	24
Subject who meets any of the following exclusion criteria will be disqualified from participation in the study:	Eligibility	25
Clinical or radiological evidence of metastatic disease	Eligibility	26
disease	DOID:4,OGMS:0000031	48-55
Prior radiotherapy, chemotherapy or biotherapy for the currently diagnosed breast cancer prior to randomization	Eligibility	27
radiotherapy	OAE:0000235	6-18
breast cancer	DOID:1612	75-88
Clinically significant pericardial effusion	Eligibility	28
pericardial effusion	HP:0001698,DOID:118	23-43
Serious cardiac illness including, but not confined to	Eligibility	29
history of documented congestive heart failure	Eligibility	30
history	BFO:0000182	0-7
congestive heart failure	HP:0001635,DOID:6000	22-46
history of any form of cardiomyopathy or active treatment for any form of cardiomyopathy	Eligibility	31
history	BFO:0000182	0-7
cardiomyopathy	HP:0001638,DOID:0050700	23-37
cardiomyopathy	HP:0001638,DOID:0050700	74-88
active	PATO:0002354	41-47
history of angina pectoris or documented transmural myocardial infarction, or active angina pectoris requiring medication	Eligibility	32
history	BFO:0000182	0-7
angina pectoris	HP:0001681	11-26
angina pectoris	HP:0001681	85-100
myocardial infarction	HP:0001658,DOID:5844	52-73
active	PATO:0002354	78-84
serious ventricular arrhythmias requiring medication or implantable cardioverter-defibrillator (ICD) therapy, uncontrolled supraventricular arrhythmias	Eligibility	33
clinically significant valvular disease	Eligibility	34
disease	DOID:4,OGMS:0000031	32-39
poorly controlled arterial hypertension (systolic blood pressure (BP) >180 mmHg, diastolic BP >100 mmHg)	Eligibility	35
hypertension	HP:0000822,DOID:10763	27-39
systolic blood pressure	CMO:0000004	41-64
Sensory/motor neuropathy > grade 2 as defined by National Cancer Institure - Common Toxicity Criteria (NCI-CTC)	Eligibility	36
neuropathy	DOID:870	14-24
cancer	DOID:162	58-64
Pregnancy, or intending to become pregnant during the study	Eligibility	37
Nursing (breastfeeding) or intending to be nursing during the study	Eligibility	38
Any of the following clinical conditions:	Eligibility	39
Chronic obstructive pulmonary disease, requiring chronic treatment	Eligibility	40
chronic obstructive pulmonary disease	DOID:3083	0-37
chronic	HP:0011010	0-7
chronic	HP:0011010	49-56
Clinically significant active infections	Eligibility	41
active	PATO:0002354	23-29
A history of a psychological illness of condition, preventing the subject to understand the requirements of the study	Eligibility	42
history	BFO:0000182	2-9
condition	PDRO:0000129	40-49
Unstable regulation of diabetes mellitus	Eligibility	43
diabetes mellitus	HP:0000819,DOID:9351	23-40
A situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study	Eligibility	44
condition	PDRO:0000129	15-24
Is on staff, affiliated with, or a family member of the staff personnel directly involved with this study	Eligibility	45
member of	RO:0002350	42-51
Usage of any investigational product within 30 days prior to enrollment	Eligibility	46
product	BAO:0003067	29-36
Participation in any other interventional clinical study involving drug, device or biological. This would not prohibit the patient from participating in a quality of life (QOL), questionnaire, blood collection, or observational study.	Eligibility	47
drug	CHEBI:23888	67-71
patient	HADO:0000008,OAE:0001817	123-130
quality	BAO:0002928,BFO:0000019	155-162
blood	UBERON:0000178	193-198
Allergy to or sensitivity to the study drug or its excipients	Eligibility	48
allergy	HP:0012393	0-7
drug	CHEBI:23888	39-43
Outcome Measurement:	Results	0
Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year	Results	1
duration	PATO:0001309	195-203
year	UO:0000036	209-213
Cardiac events defined as:	Results	2
Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of >10 percentage points from baseline and to 50% LVEF	Results	3
death	OAE:0000632	17-22
death	OAE:0000632	107-112
death	OAE:0000632	143-148
heart	UBERON:0000948	30-35
myocardial infarction	HP:0001658,DOID:5844	50-71
arrhythmia	HP:0011675	75-85
severe	HP:0012828	209-215
left	HP:0012835	251-255
ejection fraction	CMO:0000180	268-285
Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of >10 percentage points from baseline and to <50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.	Results	4
Time frame: 8 cycles of chemotherapy and subsequently one year of planned trastuzumab treatment	Results	5
time	PATO:0000165	0-4
year	UO:0000036	58-62
Results 1:	Results	6
Arm/Group Title: Pegylated Liposomal Doxorubicin (PLD) Based Regimen	Results	7
doxorubicin	CHEBI:28748,BAO:0000639	37-48
Arm/Group Description: PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)	Results	8
cyclophosphamide	CHEBI:4026	58-74
paclitaxel	CHEBI:45863	264-274
Overall Number of Participants Analyzed: 120	Results	9
Measure Type: Number	Results	10
Unit of Measure: Participants  5	Results	11
Results 2:	Results	12
Arm/Group Title: Doxorubicin Based Regimen	Results	13
doxorubicin	CHEBI:28748,BAO:0000639	17-28
Arm/Group Description: doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)	Results	14
doxorubicin	CHEBI:28748,BAO:0000639	23-34
cyclophosphamide	CHEBI:4026	69-85
paclitaxel	CHEBI:45863	176-186
Overall Number of Participants Analyzed: 59	Results	15
Measure Type: Number	Results	16
Unit of Measure: Participants  11	Results	17
Adverse Events 1:	Adverse Events	0
Total: 20/120 (16.67%)	Adverse Events	1
ANAEMIA 1/120 (0.83%)	Adverse Events	2
FEBRILE NEUTROPENIA 5/120 (4.17%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	8-19
LEUKOPENIA 1/120 (0.83%)	Adverse Events	4
leukopenia	HP:0001882,DOID:615	0-10
NEUTROPENIA 0/120 (0.00%)	Adverse Events	5
neutropenia	HP:0001875,DOID:1227	0-11
ATRIAL THROMBOSIS 1/120 (0.83%)	Adverse Events	6
thrombosis	DOID:0060903	7-17
CARDIAC FAILURE 1/120 (0.83%)	Adverse Events	7
MITRAL VALVE INCOMPETENCE 0/120 (0.00%)	Adverse Events	8
mitral valve	UBERON:0002135	0-12
MYOCARDIAL INFARCTION 1/120 (0.83%)	Adverse Events	9
myocardial infarction	HP:0001658,DOID:5844	0-21
PLEUROPERICARDITIS 1/120 (0.83%)	Adverse Events	10
ABDOMINAL PAIN 0/120 (0.00%)	Adverse Events	11
abdominal pain	HP:0002027	0-14
ABDOMINAL PAIN UPPER 1/120 (0.83%)	Adverse Events	12
abdominal pain	HP:0002027	0-14
Adverse Events 2:	Adverse Events	13
Total: 7/59 (11.86%)	Adverse Events	14
ANAEMIA 1/59 (1.69%)	Adverse Events	15
FEBRILE NEUTROPENIA 4/59 (6.78%)	Adverse Events	16
neutropenia	HP:0001875,DOID:1227	8-19
LEUKOPENIA 0/59 (0.00%)	Adverse Events	17
leukopenia	HP:0001882,DOID:615	0-10
NEUTROPENIA 2/59 (3.39%)	Adverse Events	18
neutropenia	HP:0001875,DOID:1227	0-11
ATRIAL THROMBOSIS 0/59 (0.00%)	Adverse Events	19
thrombosis	DOID:0060903	7-17
CARDIAC FAILURE 1/59 (1.69%)	Adverse Events	20
MITRAL VALVE INCOMPETENCE 1/59 (1.69%)	Adverse Events	21
mitral valve	UBERON:0002135	0-12
MYOCARDIAL INFARCTION 0/59 (0.00%)	Adverse Events	22
myocardial infarction	HP:0001658,DOID:5844	0-21
PLEUROPERICARDITIS 0/59 (0.00%)	Adverse Events	23
ABDOMINAL PAIN 1/59 (1.69%)	Adverse Events	24
abdominal pain	HP:0002027	0-14
ABDOMINAL PAIN UPPER 0/59 (0.00%)	Adverse Events	25
abdominal pain	HP:0002027	0-14
